Supinoxin

小分子

舒匹诺辛

P-P68 inhibitor RX-5902 | KAKPGJJRYRYSTP-UHFFFAOYSA-N | 1-Piperazinecarboxamide, 4-(3,5-dimethoxyphenyl)-N-(7-fluoro-3-methoxy-2-quinoxalinyl)- | SB19791 | SCHEMBL1137972 | UNII-ZU8OM8V5WF | HY-123611 | Supinoxin | RX-5902 | 1-(3,5-Dimethoxyphenyl)-4-((6-

Supinoxin

S649887-5mg

5mg

Moligand™

≥99%

-20°C储存

超低温冰袋运输

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent . Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin . Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC 50 s ranging from 10 nM to 20 nM In Vitro RX-5902 (0-10 μM; 72 hours) is active against cell lines of all TNBC molecular subtypes and is active against cell lines with mutations in p53, RB1, CDKN2A, and loss of PTEN. RX-5902 (20-100 nM; 24 hours) treatment results in a dose-dependent increase in tetraploid cells, consistent with induction of G2–M cell-cycle arrest. RX-5902 (0-100 nM; 72 hours) exhibits no significant induction of apoptosis in cell lines resistant to the antiproliferative effects of RX5902. But in sensitive cells, the observed activation of apoptosis begins at 24–48 hours and reaches a peak at 72 hours. The induced apoptosis is greasted with a dose of 100 nM. RX-5902 (0-100 nM; 24 or 48 hours) decreases MCL-1 expression as a dose-dependent manner in TNBC cell lines sensitive to RX-5902. RX-5902 inhibits cell growth, MDA-MB-231, Caki-1, UMRC2, PANC-1, A549, MKN-45, HepG2, HCT116, HT29, PC-3, U251, HeLa, SK-MEL-28 and OVCAR-3 with IC 50 values range from 0.01 μM to 0.021 μM? in the growth inhibition of cancer cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MDA-MB-231, HCC1806, Hs578t, CAL-85-1, HCC38, HCC1187, MDA-MB-436, CAL-51, HCC38, BT549, MDAMB-157, HDQ-P1, HCC1395, MDA-MB-436, HCC1937, CAL-120, BT20 cells Concentration: 0-10 μM Incubation Time: 72 hours Result: Displayed the average IC 50 of the cell lines sensitive to RX-5902 treatment is 56 nM. Cell Cycle AnalysisCell Line: Sensitive (MDA-MB-231 and HCT1806) and two resistant (MDA-MB-436 and CAL-120) cell lines Concentration: 20 nM; 100 nM Incubation Time: 24 hours Result: Led to G2-M cell-cycle arrest at sensitive cells. Apoptosis AnalysisCell Line: Sensitive (MDA-MB-231 and HCT1806) and two resistant (MDA-MB-436 and CAL-120) cell lines Concentration: 0-100 nM Incubation Time: 24-72 hours Result: Induced cell apoptosis in sensitive cell lines and peaks at 72 hours. Western Blot AnalysisCell Line: Cal-51, HCC-1806, and MDA-MB-468 cells Concentration: 20 nM; 100 nM Incubation Time: 24 hours Result: Induced inhibition of MCL-1 expression in Cal-51, HCC-1806, and MDA-MB-468 cells. In Vivo RX-5902 (oral administration; 160/320/600 mg/kg; once weekly for 3 weeks) significant dose-dependent tumor growth inhibition (TGI) in the MDA-MB-231 model, exhibits TGI of 55.7%, 80.29% and 94.58% at 160 mg/kg, 320 mg/kg and 600 mg/kg, respectively. It is more efficacious than the chemotherapy control arm of nab-paclitaxel (TGI 45%) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MDAMD-231 xenograft model in mice Dosage: 160 mg/kg; 320 mg/kg; 600 mg/kg Administration: Oral administration; once weekly for 3 weeks Result: Decreased tumor volume as a dose-dependent manner. Form:Solid IC50& Target:IC50: phosphorylated-p68 RNA helicase,apoptosis

Supinoxin（RX-5902）是磷酸化-p68 RNA 螺旋酶（P-p68）的抑制剂，也是一种强效的一级抗癌药。Supinoxin 与 Y593 磷酸化-p68 相互作用，并抑制 β-catenin 的核穿梭。

888478-45-3

C22H24FN5O4

441.46 g/mol

11619093

COC1=CC(=CC(=C1)N2CCN(CC2)C(=O)NC3=NC4=C(C=CC(=C4)F)N=C3OC)OC

4-(3,5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide

1S/C22H24FN5O4/c1-30-16-11-15(12-17(13-16)31-2)27-6-8-28(9-7-27)22(29)26-20-21(32-3)25-18-5-4-14(23)10-19(18)24-20/h4-5,10-13H,6-9H2,1-3H3,(H,24,26,29)

KAKPGJJRYRYSTP-UHFFFAOYSA-N

COC1=CC(=CC(=C1)N2CCN(CC2)C(=O)NC3=NC4=C(C=CC(=C4)F)N=C3OC)OC

11619093

888478-45-3

1-(3,5-dimethoxyphenyl)-4-((6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl)piperazine;RX-5902

DMSO : 100 mg/mL (226.52 mM; Need ultrasonic)

1

8

5

441.181 Da

441.181 Da

89.100 Ų

32

0

611.000

0

1

2.700